Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer

NCT02119676 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02119676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02119676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2014
Completion date
December 31, 2016
Enrollment
396 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

crc (colorectal cancer)